Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Haemonetics ( (HAE) ) has provided an announcement.
On January 9, 2026, Haemonetics Corporation announced it had acquired Vivasure Medical Limited in a deal comprising an upfront cash payment of €100 million—about €52 million net of prior Haemonetics investments and loans—and up to an additional €85 million in milestone-based contingent consideration, financed entirely with cash on hand. The acquisition gives Haemonetics ownership of Vivasure’s PerQseal Elite bioabsorbable large-bore vessel closure technology, which has demonstrated strong safety and performance data, received CE Mark approval in Europe in 2025 and is under U.S. FDA review, strengthening Haemonetics’ portfolio of closure devices, deepening its presence in the fast-growing structural heart and endovascular markets, and positioning the company to leverage its commercial scale and operational synergies to increase its leadership and value proposition for physicians and hospitals.
The most recent analyst rating on (HAE) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on Haemonetics stock, see the HAE Stock Forecast page.
Spark’s Take on HAE Stock
According to Spark, TipRanks’ AI Analyst, HAE is a Outperform.
Haemonetics’ overall stock score is driven by strong earnings call performance and robust financial metrics, particularly in profitability and cash flow. However, technical indicators suggest caution due to overbought conditions, and valuation metrics indicate moderate attractiveness. The company’s high leverage and revenue decline are areas to watch.
To see Spark’s full report on HAE stock, click here.
More about Haemonetics
Haemonetics Corporation is a global medical technology company that develops hospital technologies to improve standards of care and patient outcomes, end-to-end plasma collection systems for plasma centers, and blood collection products for blood centers, with a focus on addressing critical medical needs in healthcare. Vivasure Medical, based in Galway, Ireland, develops advanced polymer implants and delivery systems for minimally invasive vessel closure in cardiology, interventional radiology and vascular surgery, including its PerQseal Elite system for large-bore arterial and venous closure.
Average Trading Volume: 835,584
Technical Sentiment Signal: Strong Buy
Current Market Cap: $3.89B
Find detailed analytics on HAE stock on TipRanks’ Stock Analysis page.